Month: August 2020

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 1 In a round flask, 2 mL of methyl cyanide (acetonitrile) as an organic solvent was introduced, 0.145 g (1 mmol) of 5-chloromethylfurfural (CMF, compound I) was dissolved in the organic solvent, 0.302 g (1 mmol) of tetrabutylammonium acetate was added to the solution, and then the mixed solution was reacted at normal pressure and room temperature for 5 minutes. After the reaction, the reaction product was extracted by the addition of a small amount of water (5 mL) and ethyl acetate (added twice by 20 mL) to obtain an organic layer. The obtained organic layer was concentrated under reduced pressure to obtain light yellow liquid 5-acetoxymethylfurfural (AcHMF, compound II). The yield thereof is 97%. It was ascertained by 1H-NMR that the light yellow liquid is a target material. Analysis data is as follows. AcHMF: 1H NMR (400 MHz, CDCl3) 9.65 (s, 1H), 7.25 (d, J=3.6, 1H), 6.62 (d, J=3.6, 1H), 5.13 (s, 2H), 2.12 (s, 3H)

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kim, Baek Jin; Cho, Jin Ku; Kim, Sangyong; Lee, Do Hoon; Kim, Young Gyu; Kang, Eun-Sil; Hong, Yeon-Woo; Chae, Da Won; US2015/51413; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4062-60-6,N1,N2-Di-tert-butylethane-1,2-diamine,as a common compound, the synthetic route is as follows.

Concentrated HCl (3.0 mL) was slowly added under cooling to N,N-di-tert-butylethylenediamine (1.0 mmol). Solvent was removed by rotary evaporator. Then trimethyl orthoacetate (10.0 mL) and 2 drops of formic acid were added. The mixture was stirred for 48 h at 120C. Solvent was removed and the white greasy solid was washed with THF and dried under reduced pressure. Yield: 0.11 g, 44%. 1H NMR (400 MHz, CDCl3): delta 4.15 (s, 4H), 2.61 (s, 3H), 1.57 (s, 18H) ppm; 13C NMR (100 MHz, CDCl3): delta 165.4, 57.8, 45.8, 29.1, 16.2 ppm.

4062-60-6 N1,N2-Di-tert-butylethane-1,2-diamine 77680, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Lu, Bing; Zhu, Fan; Wang, Dan; Sun, Hongmei; Shen, Qi; Tetrahedron Letters; vol. 58; 25; (2017); p. 2490 – 2494;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(1)To a solution of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate tri-tert-butyl (24.8 mg), DMF (0.2 mL) and DIEA (17 muL) was added HBTU (17.0 mg) in DMF (100 muL), and then added to a solution of (L 7) (13.1 mg) in DMF (200 muL) and DIEA (10 muL) and stirred at room temperature for 1 hour. Water (200 muL) was added and purified by preparative HPLC to give (M 1) (12.3 mg).

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2390-68-3,N-Decyl-N,N-dimethyldecan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Decyldimethylammonium bromide (0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. Sodium dihexylsulfosuccinate (Colawet MA-80 from Colonial Chemicals, South Pittsburg, Tenn.; 0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. The two solutions were combined and the reaction mixture was heated and stirred for 30 minutes. The reaction mixture cooled to room temperature and then 60 mL of chloroform was added. The reaction mixture was stirred for an additional 30 minutes. The two phases were separated and the chloroform phase was washed several times with cool distilled water to remove any inorganic salt. The presence of chloride anions was monitored by silver nitrate test. A rotary evaporator removed the chloroform and a yellowish viscous liquid was obtained in 96.93% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=liquid at room temperature. Thermal data determined by thermalgravimetric analysis (TGA): Tonset5%=218 C. and Tonset=226 C.

2390-68-3 N-Decyl-N,N-dimethyldecan-1-aminium bromide 16957, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: 1H-NMR spectra were recorded on a DRX 400 (9.4 T, 400.13 MHz) spectrometer (Bruker Espanola S.A., Madrid, Spain) at 300 K. The [Host] values in the range of 1.02 to 1.85 ¡Á 10-3 correspond to a weighted quantity of host in 2 mL of CDCl3 (S33657, deuterium content >99.8%, water content <0.01%, containing silver wire as stabilizer, Merck S.L., Mollet del Valles-Barcelona, Spain). A given quantity of the guest (about 2 ¡Á 10-2 M) was weighed in a 1 mL volumetric flask and host solution was added to reach the graduation mark; in this way we know that the host concentration remains constant. Host and guest were weighted in a AE260-Delta Range scale (error ¡À 0.00005 g, Mettler Toledo, L' Hospitalet de Llobregat-Barcelona, Spain) and eVol XR hand-held automated analytical syringes (500 muL, 50 muL) from SGE Analytical Science (Trajan Scientific Europe Ltd, Crownhill, Milton Keynes, United Kingdom) previously calibrated for CDCl3, were used to perform additions. 1H-NMR titrations were used to quantify Ka values (see Figure 5 for two representative plots). 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various. Reference£º
Article; Garcia, M. Angeles; Farrn, M. Angeles; Mara, Dolores Santa; Claramunt, Rosa M.; Torralba, M. Carmen; Torres, M. Rosario; Jaime, Carlors; Elguero, Jos; Molecules; vol. 20; 6; (2015); p. 9862 – 9878;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: A solution of x,y-bis(bromomethylnaphthalene) (x,y = 2,7, 2,6 or 1,6) (2,7-bis(bromomethyl)naphthalene;126 mg, 400 mumol / 2,6-bis(bromomethyl)naphthalene; 72.0 mg, 100 mumol / 1,6-bis(bromomethyl)naphthalene; 31.4 mg, 100 mumol)S1 was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (50.1 mg, 100 mumol), KI (16.6 mg, 100 mumol) and K2CO3(10.8 mg, 78.0 mumol) in CH3CN (3.50 mL) under N2 and stirred for 24 h at room temperature. The reactionmixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washedwith water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Bocprotectedamine intermediates. A solution of the intermediates was added to bis(pyridin-2-ylmethyl)amine(Dpa) (12.0 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc.The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtainthe corresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved inCHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6.0 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 1-3.

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1067-33-0,Dibutyltin diacetate,as a common compound, the synthetic route is as follows.

[Example 7] 306 g of a residual liquid were obtained by carrying out the same method as Example 6 with the exception of using 255 g of di-n-butyl tin diacetate, and using 961 g of 3-methyl-1-butanol (Tokyo Chemical Industry Co., Ltd., Japan) instead of 2-ethyl-1-butanol. The residual liquid contained 92.7% by weight of di-n-butyl-bis(3-methylbutyloxy) tin. In addition, the low boiling point component contained 18.0% by weight of isoamyl acetate.

The synthetic route of 1067-33-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Asahi Kasei Chemicals Corporation; EP2226328; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (y = 3 or 4) (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (30.0 mg, 60.0 mumol) in MeOH (1.00 mL) andAcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (7.50 mg, 120 mumol) wasadded to the reaction mixture slowly and stirred at room temperature for 20 h. The reaction mixture waspoured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was thenwashed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain thecorresponding tri-N-Boc-protected amine intermediates. The intermediates were then dissolved in CHCl3(2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentratedunder reduced pressure and purified by preparative HPLC to obtain the desired compounds 19-22.

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: 4,4?-Dmo-2,2?-bpy (0.22 g, 1 mmol) was placed in oneof the arms of a branched tube [32], and zinc(II) acetatedihydrate (0.11 g, 0.5 mmol) and potassium thiocyanate(0.10 g, 1 mmol) were placed in the other arm. Ethanoland water in a ratio of 3:2 were carefully added to fill botharms. The tube was then sealed and the ligand-containingarm was immersed in a bath at 60¡ãC, whereas the otherwas maintained at ambient temperature. After 1 day, crystalsthat were deposited in the cooler arm were filtered off,washed with mother liquid, and dried in air, yield: 0.18 g,59percent.

As the paragraph descriping shows that 17217-57-1 is playing an increasingly important role.

Reference£º
Article; Marandi, Farzin; Moeini, Keyvan; Rudbari, Hadi Amiri; Zeitschrift fur Naturforschung, B: Chemical Sciences; vol. 71; 9; (2016); p. 959 – 965;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2390-68-3,N-Decyl-N,N-dimethyldecan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Example 3. Preparation of Didecyldimethylammonium-Omadine Compounds[0069] Didecyldimethylamonium bromide (81.4 g, 75%> gel in water, 0.17 mol) was added to sodium omadine (56 ml, 28.2g, 0.2 mol) solution, mixed well and stirred for 2 hrs. Collect the desired product (top brown oil) and wash it with braine (saturated NaCl solution), dry it. Weight 102.2g (133%) yield containing water, structure is not fully assigned yet with NMR).

As the paragraph descriping shows that 2390-68-3 is playing an increasingly important role.

Reference£º
Patent; LIU, Huiwen; ZHANG, Boke; WO2012/12049; (2012); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI